Open AccessNew‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
Author(s) -
Guida Agostino,
Perri Francesco,
Ionna Franco,
Ascierto Paolo A.,
Grimaldi Antonio M.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3418
Subject(s) - medicine , osteonecrosis of the jaw , ipilimumab , multidisciplinary team , chemotherapy , immunotherapy , dermatology , surgery , bisphosphonate , cancer , osteoporosis , nursing
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.